Venture Life Share Discussion Threads

[apad] 24/11/2016 06:33

att
You will find these (good) points debated on the Paul Scott Small Cap Value site.

Intertek is not a good comparator.

Growth is acquisition plus organic.

apad

[attrader] 23/11/2016 21:36

PTSG is an interesting little company. I have been reading about it over the weekend. And i have more questions than answers. Will be thankful if others have a view on it.

How does PTSG testing services compare in quality with the likes of Intertek?

Who are their main competitor? Can they compete with them on pricing and generate higher ROIC? What is source of their competitive advantage?

Since they are buying up companies, debt has been going up significantly. Their strategy is based on acquisitions requiring significant capital outlay. Are they being prudent about their borrowings? Can a business slow down in the future create difficulties in servicing a large pot of debt? Will they issue more shares to raise capital for acquisitions?

Why have the receivables gone up so much in the last year?

[apad] 23/11/2016 19:50

My decision was based on the notion that PTSG does not have to run expensive plant, d.
If the infrastructure spending does take off then the plant, if fully utilised, will be a boost, else a drag.
Let's keep a comparison going.
apad
ps
VANL looks a good company to me - these are nuances. However, I am more and more sensitive to context.

[apad] 23/11/2016 18:04

I just wondered if the tip had boosted the price and, if so, by how much for how long, d.
Be interesting to see how my PTSG choice will compare. Warrants issued associated with the flotation caused recent liquidity, but I have no funds.

Listening to CNN it is clear that the yoodles see the financials going to town based on Trump and the reduction of rules. I reckon this is the dominant narrative for a while so the GSK fundamentals I see are simply of no interest.

apad

[lauders] 23/11/2016 15:44

For GSK bulls/holders:



The reaction to Donald Trump’s election victory has been surprising. First, stock markets sank. Then they rose. Now at the time of writing they are falling once more. Clearly, the only thing that investors can be certain of is that uncertainty will be high over the short to medium term.

Part of the reason for this is that Trump is a known unknown. He has no long-term track record in politics and it is impossible to know exactly what policies he will pursue. In fact, there is a good chance that even he does not yet know exactly how he will seek to improve the US economy. That’s why in my view it’s a good idea to own companies which have a relatively low positive correlation with the economy. One example of this is GlaxoSmithKline (LON:GSK), which I believe will outperform a volatile wider index over the medium term.

[apad] 23/11/2016 14:21

Isn't there a Daily Mail tip influence with VANL, dacian?

About time I was right about something, red!

Right approach with TRCS in my opinion, PJ1. But I would wait for the news before entering. Too many long-term holders bailed out and the latest FY read exactly like a year old. Paul Scott said he would be soliciting for questions with his annual interview with the CEO today - but it has all gone quiet.

apad

[redartbmud] 23/11/2016 13:51

dacian

Thanks. I have broad shoulders.

red

[redartbmud] 23/11/2016 09:33

dacian

Good call. I think that you are on the right lines. I started my due diligence but had to go out before I finished. The share price then started to move before I got back into it. Just shows that instinct can be a valuable tool - or not in some cases.

red

[pj 1] 23/11/2016 09:32

TRCS- Its hard to tell if the chart is rolling over or consolidating. A nice long consolidation would be nice for a re-entry (coupled with news )

[redartbmud] 23/11/2016 08:53

APAD

Your call on Ror was right.

red

[redartbmud] 23/11/2016 07:59

Thanks - thin finger?

red

[apad] 22/11/2016 21:40

edited :-)
apad

[redartbmud] 22/11/2016 21:35

At £7 I might be bottom fishing for Gsk.

red

[apad] 22/11/2016 21:24

I think the TRCS story has changed. So, it's more of a reduction policy, red.

GSK still on the top-slice agenda, but over £17 :-)

apad

[redartbmud] 22/11/2016 20:30

APAD

I thought that you had resolved not to top slice in future. Was I mistaken?

red

[apad] 22/11/2016 20:09

ps
My 8k XMAS forecast for the FTSE looks more than a little unlikely.
However,this level seems to be artificially depressed.

[apad] 22/11/2016 20:04

225 floor on ROR I reckon.
More oil and dollar strength on the way.
Company specific worries gone away.
Bifold inspires zero confidence.

HLMA, typical conservative reporting (without too much currency tailwind emphasis) should inspire some weakness. Some ludicrous actuarial pension comments for the wary. Nothing at all worrying.
Worth watching for dips.

Should've top-sliced TRCS more.

apad

[redartbmud] 22/11/2016 17:36

Agreed, Ror has fallen more than most, and that was my first thought, when I was disposed not to sell. Having given much thought, a significant amount of the profit is coming from currency for the current year viz:

Outlook

The trading environment is anticipated to remain challenging across most of our key markets and geographies. Margins are expected to be lower than the prior year, as previously indicated, but in line with market expectations. Currency continues to provide a tailwind, and based on current exchange rates is now expected to deliver a 10% benefit to both full year revenue and profit.

It was the margins wot done it guv, coupled with the indigestion at Bifold.

Buying back around £2 would be a nice little deal that might just happen when Opec et al fall out again.
I don't see them at £2,50 in the short term.
Time will tell if I am right, and there may be some sellers in the morning. 13% gain on the results is a big call.

red

[apad] 22/11/2016 17:14

ps
Also ROR has fallen more than most.